.png?width=1200&height=236&name=Causaly%20logo%20(Medium).png "CausalyBlackLogo")
Target Identification in Oncology: How R&D teams accelerate target identification with evidence-backed insights
Oncology represents 23% of global R&D investment and 41% of all clinical trials in 2024. But only around 5% of drugs entering Phase gain approval. Lack of efficacy accounts for 40–60% of late-stage failures, many of which can be traced back to target selection.
This ebook explores how leading R&D teams are strengthening target identification with a more complete and traceable evidence base, reducing risk, and advancing programs with greater confidence.
Inside the ebook
- Why 40–60% of oncology drug failures trace back to target selection decisions
- The evidence areas required to support a target, and why most evaluations assess only a subset of them
- Real-world examples of teams reducing candidate lists from thousands to hundreds in hours, surfacing targets that manual review would miss.
Download the eBook.
Download the eBook
Trusted by the world's leading pharmaceutical companies
%20small.png?width=200&height=73&name=Teva%20Logo%20(Website)%20small.png)
.png?width=99&height=97&name=ProQR%20logo%20(1).png)
How Causaly helps with Target ID
Teams report up to 90%+ time savings and 5x–10x productivity improvements, with time reallocated to higher-value scientific work. ProQR met their 2024 target identification goal by Q3 and achieved 5x productivity compared to PubMed, with 50% of targets pitched informed by Causaly insights.
Causaly's knowledge graph covers 500M+ facts and 70M+ directional relationships across tens of millions of documents, with high precision and continual updates. Target nomination packages carry the full evidence trail, making them defensible to internal committees, leadership, and regulatory reviewers in a way that manually assembled shortlists cannot be.
Teams report up to 90%+ time savings and 5x–10x productivity improvements, with time reallocated to higher-value scientific work. ProQR met their 2024 target identification goal by Q3 and achieved 5x productivity compared to PubMed, with 50% of targets pitched informed by Causaly insights.
"Causaly helped us unearth more hidden links much faster than if we were to go through the paper, read it, and hope the author mentions what we are interested in. PubMed wouldn't be a substitute."
Bart Klein, SVP Head of Axiomer Strategy,
ProQR.